In i6 workers with lead poisoning of varying degrees, a comparison was made between the therapeutic efficacy of sodium calciumedetate (Ca-EDTA) and penicillamine (PCA), administered intravenously and orally. The question of comparable dosages of ligands, forming metal complexes in different ways, is discussed. With the dosages given, intravenous Ca-EDTA promoted the greatest output of lead in the urine, followed by intravenous and oral PCA. These three agents also had a very satisfactory effect on the output of 8-aminolaevulinic acid (ALA) in urine. Oral Ca-EDTA was found to be greatly inferior in both these respects.
In i6 workers with lead poisoning of varying degrees, a comparison was made between the therapeutic efficacy of sodium calciumedetate (Ca-EDTA) and penicillamine (PCA), administered intravenously and orally. The question of comparable dosages of ligands, forming metal complexes in different ways, is discussed. With the dosages given, intravenous Ca-EDTA promoted the greatest output of lead in the urine, followed by intravenous and oral PCA. These three agents also had a very satisfactory effect on the output of 8-aminolaevulinic acid (ALA) in urine. Oral Ca-EDTA was found to be greatly inferior in both these respects. In order to study the absorption of the agents and the renal excretion of the formed lead complexes, the urine was collected quantitatively and fractionated in consecutive 4-hour periods, after which the lead excretion during each period was determined. It was found that the oral absorption of PCA was rapid and quantitatively great, whereas the oral absorption of Ca-EDTA was very slow and quantitatively small. The possible resorption of ligand-lead complexes is discussed and indications were found of resorption of the Ca-EDTA-lead complex but not of the PCA-lead complex. The renal excretion of the different ligand-lead complexes was very effective and reached its maximal level within four hours. However, in some subjects excretion of the Ca-EDTA-lead complex showed some delay. An investigation, in four subjects, of a blocking effect of probenecid on the renal excretion of PCA and/or PCA-lead complexes gave no conclusive results. It is concluded that oral PCA is satisfactory in most cases of lead poisoning. However, in more severe cases intravenous treatment is preferable. Which agent should be chosen, Ca-EDTA or PCA, appears to be unimportant as both are quite satisfactory from the point of view of treatment, but it seems that Ca-EDTA may cause more serious side-effects. Oral Ca-EDTA is quite unsatisfactory and there is good evidence to indicate that the agent causes a resorption of Ca-EDTA-lead complexes from the gastro-intestinal tract.
Intravenous sodium calciumedetate (Calcium Disodium Versenate-Ca-EDTA) and oral penicillamine (PCA) have been proved to be effective in the treatment of lead poisoning (Bessman, Ried, and Rubin, I952; Foreman, Hardy, Shipman, and Belknap, 1953;  Rieders, Dunnington, and Perol, Graveleau, Potter, and Morin, I962; Goldberg, Smith, and Lockhead, I963; Moncrieff, Koumides, Clayton, Patrick, Renwick, and Roberts, I964; Caccuri and Pecora, I965; Selander, Cramer, and Hallberg, I966) . Isolated cases have been reported in which PCA has been given intravenously with good results and without side-effects (Haeger-Aronsen, I960; Ohlsson, I962) . Opinions on the efficacy of oral Ca-EDTA are divergent, despite the fact that it has been clearly shown that the agent is very poorly absorbed (only between 2 and 5 %) from the gastrointestinal tract (Srbova and Teisinger, I957; Foreman, I960) . Thus, some authors maintain that it is effective (Manville and Moser, I955; Bell, Gilliland, Boland, and Sullivan, I956; Williams,  Matthews, and Judd, I962), whereas others consider oral Ca-EDTA to be contraindicated because it increases the absorption of lead from the gut and in this way can even precipitate or increase the symptoms of poisoning (Kehoe, I955; Rieders and Breiger, 1955; Byers, I959b; Rieders, I960).
Treatment of Lead
There are few comparisons in the literature between the agents and the various methods of administration and the results are contradictory (Sidbury, Bynum, and Fetz, I953; Harris, 1958; Mosser and Bessman, I960; Ohlsson, I962, I963; Moncrieff et al., I964; Caccuri and Pecora, I965) . Therefore, the purpose of the present work was to make a comparative study in a number of hospital in-patients, since uniform treatment and careful supervision were possible, especially the quantitative collection of urine.
The possibility that probenecid might block the urinary excretion of PCA, in the same way that it blocks the tubular excretion of some organic acids, was also studied. an exception to this in that in all cases the treatment ended with intravenous Ca-EDTA. The dosage was the same, I g. at 7 a.m. and I g. at 7 p.m., for both the agents as was the method of administration. Oral PCA was given as capsules containing 250 mg. and, for intravenous injection, a 5% solution was prepared from the substance supplied by Merck, Sharpe, and Dohme, Inc. Ca-EDTA was given intravenously as a io% solution and the same solution was also used orally, in order to obtain optimal conditions for absorption.
The possibility that probenecid might have a blocking effect on the excretion of PCA was investigated in treatment group 2. After four days' treatment with oral and intravenous PCA alternately, the treatment in these four cases was continued for two days with oral PCA together with 2 g. probenecid daily (Table I) .
Within the three treatment groups the effects of the different agents and methods of administration on lead excretion were estimated by comparing the means of their percentage share of the total lead excretion (Table III and Fig. i) .
During the whole course of treatment in groups 2 and 3, and during the first four or five days in group i, the urine was collected in consecutive periods of four hours, starting at 7 a.m. However, the two periods during the night were combined to one period of eight hours between ii p.m. and 7 a.m. At the end of each period the patients emptied the bladder before starting the collection of urine for the next period. The lead excretion during each period was determined. For the different types of treatment the means of the excretions during the periods were calculated, expressed as a percentage of the 24-hours' excretion. The purpose was to investigate the variations within the 24-hours' lead excretion during treatment with the different agents in order to obtain information about their absorption and excretion in the urine as lead-complexes.
The urinary output of 8-aminolaevulinic acid (ALA) was followed daily. The concentration of lead in whole blood was determined before and after treatment and, in order to reveal possible side-effects, the tests described in a previous paper were performed (Selander et al., I966) .
Results

Efficiency in Promoting Lead Excretion
The results are given in Tables II and III and in Figure i . Table II shows the amount of lead excreted during each day of treatment and the total for each patient. Table III shows for the three treatment groups, the means for the percentage of lead excretion for which the different agents were responsible. The levels of significance for the differences between the means within each group are also given. Figure i shows the different effects on lead excretion. It is evident that the effect of oral PCA was superior to that of oral Ca-EDTA no matter which agent began the treatment (P<o-ooi). On the other hand, intravenous Ca-EDTA promoted a greater lead excretion than oral PCA, in spite of the fact that the former was always used at the end of treatment (P<o-OOI).
The comparison between the effects of oral and intravenous PCA showed a greater lead excretion after intravenous therapy (P<o-ooi). Finally, in the third treatment group intravenous Ca-EDTA caused a greater lead excretion than intravenous PCA (P<o-ooi).
The variations in the 24-hours' lead excretion during treatment with the different agents are shown in Figure 2 . The means for lead excretion during the different periods of diuresis, expressed as a percentage of the total daily excretion, and tests of the differences between the means, are given in Table IV .
Intravenous therapy with Ca-EDTA and PCA had a very similar and regular effect on lead excretion, with pronounced maxima and minima during the 24 hours. After each dose there was a striking peak of lead excretion within four hours, and the smallest excretion was noted after eight to I2 hours. As mentioned previously, the two periods of diuresis during the night were combined into one period of eight hours between ii p.m. and 7 a.m., which explains why the same means for lead excretion are given during these two 4-hour periods. In fact excretion during the period between i i p.m. and 3 a.m. was probably higher and that during the period between 3 and 7 a.m. lower than the calculated mean for the whole 8-hour period.
In two respects the effects of the agents were somewhat different. Thus, the second injection, at 7 p.m., gave a more pronounced maximum after PCA than after Ca-EDTA. The difference is significant (P<o-os). Further, on some occasions a delay in lead excretion was observed after the injection of Ca-EDTA, so that it did not reach the maximal level until four to eight hours after the dose at 7 a.m., but such a delay never occurred (P0P P.,) after PCA injection. This is also evident from the fact that after the injection of Ca-EDTA the lead excretion during the second period of diuresis was greater, in relation to the 24-hour amount, than it was after PCA. The difference was significant (P<o-oi), and the difference between the means for lead excretion during the first and second periods of diuresis was of a smaller significance during treatment with Ca-EDTA (P<o-o5) than with PCA (P<o-ooi) (Table IV) .
Oral therapy with PCA gave the same pattern of lead excretion as intravenous Ca-EDTA. The maxima and minima of excretion seemed to be somewhat less pronounced (Fig. 2) 3-7J *The night periods were combined into one sample, and the mean lead excretion for this sample was divided equally between both 4-hour periods.
of diuresis were not significant. Consequently, the difference in effect between oral and intravenous PCA therapy was the same as between intravenous Ca-EDTA and intravenous PCA therapy. Thus, on some occasions after the dose of oral PCA at 7 a.m. a delay of maximal lead excretion to the second period of diuresis was observed, so that the mean for this period was significantly higher than it was during treatment with intravenous PCA (P<o-oi). This delay is also evident from the fact that the difference in lead excretion between the first and second periods of diuresis was of lesser
group.bmj.com on October 27, 2017 -Published by http://oem.bmj.com/ Downloaded from significance during oral than during intravenous PCA treatment (Table IV) . Further, after the second dose the peakof lead excretion was not quite as high as it was after intravenous PCA. The difference between the means is significant (P<o-oi). Comparing oral and intravenous PCA, there were no other significant differences between the means for lead excretion during corresponding periods of diuresis.
Oral Ca-EDTA did not produce the same variations in the 24-hour lead excretion as did the other agents, although there seemed to be a tendency towards maximal and minimal excretion during the corresponding periods of diuresis. Thus, the differences between the means for excretion during the different periods of Udiuresis were not significant, except for the comparison between the first and third periods (Table IV) . In individual cases the maximal excretion occurred at different times after a given dosage of oral Ca-EDTA, and in several cases there were hardly any noticeable variations in lead excretion during the 24 hours.
Effects on the Output of ALA in Urine The ALA output is a direct measure of a metabolic effect of lead poisoning (Haeger-Aronsen, I960; Cramer and Selander, I965). Table II shows, for each patient, the manner in which the concentration of ALA was influenced by treatment. In treatment groups 2 and 3, it is evident that there was a prompt and pronounced reduction of the ALA output. In group i, however, the results were somewhat different. Figure 3 shows No side-effects were observed during the comparatively brief courses of treatment.
Discussion
As can be seen from the laboratory values and the amount of lead excreted during treatment, there were marked variations in the degree of lead poisoning among the patients (Table I ). In a previous paper (Cramer and Selander, I965) we showed that there is a very strong correlation between the ALA output in urine and the amount of lead which is excreted during a fixed course of treatment. In this respect two patients in this series (IX and XIII) seemed to be atypical, because they had a lower initial ALA concentration in relation to the total lead excretion during treatment. In patient IX this can be explained by the fact that the lead excretion was somewhat greater than usual because this patient, unlike the others, was treated only a day or two after his last exposure to lead. In patient XIII the exceptionally high diuresis may have contributed to the relatively low concentration of ALA in the urine. In the seven patients in whom a sternal puncture was performed, the changes in the bone marrow were the same as previously observed (Selander et Considering that the PCA molecule is 3-dentate, it is probable that chelate is formed. However, the -S-group can favour 1-dentate coordination owing to its pronounced capacity for binding lead. The coexistence of different types of complexes is also possible (Osterberg, I967, personal communication). Another method of comparing the effects of two agents, which might have been the most appropriate in this case, is to give both agents in the highest possible dosage without causing serious side-effects, but, since that is not without certain risks, it was deemed inadvisable in this study.
Accordingly it was decided to base the comparison on equal quantities by weight, using 2 g. Ca-EDTA a day intravenously as a reference dosage, since that is a common dosage which also is approximately the maximal advisable dosage for daily treatment. Such a comparison has its deficiencies and it ought to be to the disadvantage of PCA, which can be given in substantially higher dosages without considerable risk of more severe side-effects.
Therapeutic Effect For a comparison of the effects of the agents on lead excretion, the percentage of total excretion was chosen as themeasure, instead of the increase in lead concentration in the urine. This was because the initial values for lead concentration are not particularly well correlated Intravenous Ca-ED TA and PCA With intravenous treatment the difference in effect between Ca-EDTA and PCA was not as evident in the two most intoxicated patients as in the other two. A possible explanation is that Ca-EDTA, to a greater degree than PCA, is able to form complexes with lead that is less accessible. This difference is then less noticeable the more intoxicated the patients are, i.e., the more 'easily accessible' lead there is. The satisfactory effect of both these agents on lead excretion and their ability to produce a rapid and pronounced reduction of ALA output seem to make it immaterial which should be chosen for intravenous treatment. However, it is not known whether there are any important long-term differences in their effectiveness. This could only be determined by a long-term follow-up of patients who were no longer exposed to lead after the end of treatment. From our present knowledge of the side-effects of these drugs, PCA should probably be preferred. The lead complexes formed were excreted by the kidneys at approximately the same rate, which is evident from the fact that the maximal and minimal lead excretion appeared within the same period after the agents were given (Fig. 2) . However, the delay in excretion of the lead complexes, which was observed in some cases after Ca-EDTA, but not after PCA, has a practical significance primarily in diagnostic mobilization tests. Thus, after a test dosage of intravenous PCA, collection of urine for four hours is sufficient whereas the urine must be collected for eight hours after Ca-EDTA to ensure obtaining maximal lead excretion. Teisinger and Srbovai (I959) found a maximal lead concentration in the urine three to nine hours after intravenous Ca-EDTA, but the investigation was done on spot samples and not with fractionated quantitative collection of urine. The value of mobilization tests with quantitative urinary collection for 24 hours has been emphasized by Rieders (I960).
However, the author is of the opinion that the collection of urine during a much shorter period should suffice, and he suggested investigations on this subject.
Intravenous and Oral PCA This comparison
showed that, although lead excretion following intravenous PCA was higher than following oral PCA, the latter caused a substantial excretion of lead and therefore oral therapy is sufficient in most cases and further, that oral PCA must have been absorbed to a great extent. This is true provided that the increased lead excretion was not due to a resorption of PCA-lead complex from the gastrointestinal tract. That this could not have occurred in any quantity is evident from the beneficial effect of the treatment on the metabolic manifestation of lead poisoning expressed as the ALA output in urine.
Thus, on average, the ALA concentration was reduced by 70 % as early as the first two days after treatment with oral PCA (Fig. 3) . In a previous paper it was shown that the concentrations of ALA in urine and of lead in blood decreased in parallel fashion during this treatment. Such a rapid effect on the ALA output during treatment with oral PCA has also been reported by Goldberg et al. (I963) and by Caccuri and Pecora (I965) . Not only was the major part of the administered PCA absorbed but it was also absorbed rapidly, which is evident from the fact that after a given dosage the peak of lead excretion was registered within four hours in the same way as after the intravenous injection of PCA and Ca-EDTA (Fig. 2) . The delay in maximal lead excretion to the second period of diuresis observed in some patients, as was the case after the intravenous injection of Ca-EDTA, was here probably not dependent upon the excretion rate of the lead complex by the kidneys. As has been seen, there was no such delay of maximal lead excretion after intravenous PCA, and the formed PCA-lead complex should reasonably be excreted at the same rate whether PCA was given intravenously or orally. Consequently, the delay after oral administration of PCA probably depended on a somewhat slower absorption in those patients. Shapiro, I960) . This question has been discussed by several authors and frequently their opinions differ. Byers (1959a) and Rieders (I960) were convinced that the increased lead excretion in the urine depends on an absorption of Ca-EDTA-lead complex and they consider oral Ca-EDTA to be contraindicated. Kehoe (I955) was of the same opinion, and he warned against using the agent, above all as a prophylactic during lead-exposed work. On the other hand, Manville and Moser (1955) In comparison it can be mentioned that the only patient (IX) in this study who had a similar concentration of lead in the blood (ioo Hg./Ioo ml.) excreted 9 64 mg. of lead during 24 hours on a treatment of 2 g. PCA orally (Table II) . Neither were the effects on lead concentration in the blood and on the output of coproporphyrins in the urine convincing, and not infrequently there was an initial increase of values during treatment. These facts are in agreement with the observation in this investigation that the effect on the concentration of ALA in the urine was poor also when the lead excretion in the urine seemed to be relatively good, as for example in patient VI. The same experience was reported by Tishkoff, Granville, Rosen, and Dameshek (1958) .
These unsatisfactory effects on the concentration of lead in the blood, and on the output of coproporphyrins and of ALA in the urine, in spite of a maintained increase of lead excretion, are observations which support the idea that oral Ca-EDTA binds lead available in the intestines, after which this Ca-EDTA-lead' complex is absorbed. To In none of the four patients was a smaller lead excretion noted than was expected, nor was there any increase in excretion when treatment with probenecid was stopped. The tendency in subjects IX and X to a maintained increase in lead excretion during the administration of probenecid was not sufficient to conclude that probenecid had a blocking effect on PCA excretion.
Thus, the results are in favour of the third alternative, i.e., probenecid has no effect on the renal excretion of PCA and PCA-lead complexes, but further investigation would be of interest. 
